Tech Company Financing Transactions

Vigilant Biosciences Funding Round

On 7/11/2016, Vigilant Biosciences raised $5 million in Series B funding from private investors, venVelo and White Owl Capital.

Transaction Overview

Announced On
7/11/2016
Transaction Type
Venture Equity
Amount
$5,000,000
Round
Series B
Proceeds Purpose
Vigilant expects to use the funds to support numerous commercial and development efforts, including the international commercialization of its OncAlert™ Oral Cancer product line and the advancement of its OncAlert Labs product line. Additionally, the funds raised will support the continued research and development of additional products in Vigilant's pipeline.

Company Information

Company Status
Private & Independent
Industry
Medical Devices & Instruments
Mailing Address
6301 NW 5th Way 1500
Ft. Lauderdale, FL 33309
USA
Email Address
Overview
Vigilant Biosciences is a leading innovator and developer of solutions that aid in the early detection and intervention of cancer.
Profile
Vigilant Biosciences LinkedIn Company Profile
Social Media
Vigilant Biosciences Company Twitter Account
Company News
Vigilant Biosciences News
Facebook
Vigilant Biosciences on Facebook
YouTube
Vigilant Biosciences on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
William Brodie
  William Brodie LinkedIn Profile  William Brodie Twitter Account  William Brodie News  William Brodie on Facebook
Chief Financial Officer
Robert Hamilton
  Robert Hamilton LinkedIn Profile  Robert Hamilton Twitter Account  Robert Hamilton News  Robert Hamilton on Facebook
Chief Medical Officer
Michael Donovan
  Michael Donovan LinkedIn Profile  Michael Donovan Twitter Account  Michael Donovan News  Michael Donovan on Facebook
Chief Scientific Officer
Elizabeth Franzmann
  Elizabeth Franzmann LinkedIn Profile  Elizabeth Franzmann Twitter Account  Elizabeth Franzmann News  Elizabeth Franzmann on Facebook
VP - Operations
Tony Lavecchia
  Tony Lavecchia LinkedIn Profile  Tony Lavecchia Twitter Account  Tony Lavecchia News  Tony Lavecchia on Facebook
VP - Regulatory Affairs
Kris Foss
  Kris Foss LinkedIn Profile  Kris Foss Twitter Account  Kris Foss News  Kris Foss on Facebook


 

 

Browse more venture capital transactions:

Prev: 7/8/2016: ZIOPHARM Oncology venture capital transaction
Next: 7/11/2016: CornerJob venture capital transaction

 

Share this article

 


Where The Data Comes From

We do our best to record every notable VC transaction. VC investment data records on this site are sourced from publicly available VC deal announcements. The information is sourced from VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary